A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy

• Status: Terminated
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cisplatin; Pemetrexed

Criteria

Inclusion Criteria:

• Measurable disease with diagnosis of Small Cell Lung Cancer.

• Performance status of 0 to 1 on the Eastern Cooperative Oncology Group performance status schedule.

• Patients must be at least 18 years of age and have at least a 12-week life expectancy.

• No prior chemotherapy and/or prior thoracic radiotherapy.

• Adequate pulmonary function and organ function.

Exclusion Criteria:

• Patients with myocardial infarction within the preceding six months.

• Diagnosis of a serious concomitant systemic disorder.

• Prior radiotherapy to the lower neck or abdominal region.

• Significant weight loss.

• Concurrent administration of any other antitumor therapy.